Bessemer Group Inc Vertex Pharmaceuticals Inc Transaction History

Bessemer Group Inc

  • $61.3 Billion
  • Q4 2024

A detailed history of Bessemer Group Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Bessemer Group Inc holds 7,177 shares of VRTX stock, worth $3.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,177
Previous 14,790 51.47%
Holding current value
$3.5 Million
Previous $6.88 Million 58.0%
% of portfolio
0.0%
Previous 0.01%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025
SELL
$396.64 - $516.74 $3.02 Million - $3.93 Million
-7,613 Reduced 51.47%
7,177 $2.89 Million
Q3 2024

Nov 12, 2024
BUY
$460.0 - $505.78 $896,540 - $985,765
1,949 Added 15.18%
14,790 $6.88 Million
Q2 2024

Aug 13, 2024
BUY
$392.81 - $485.53 $92,703 - $114,585
236 Added 1.87%
12,841 $6.02 Million
Q1 2024

May 13, 2024
BUY
$407.69 - $446.08 $3.75 Million - $4.1 Million
9,193 Added 269.43%
12,605 $5.27 Million
Q4 2023

Feb 09, 2024
SELL
$343.0 - $410.68 $170,128 - $203,697
-496 Reduced 12.69%
3,412 $1.39 Million
Q3 2023

Nov 13, 2023
BUY
$338.18 - $362.46 $154,548 - $165,644
457 Added 13.24%
3,908 $1.36 Million
Q2 2023

Aug 10, 2023
BUY
$314.42 - $351.91 $335,486 - $375,487
1,067 Added 44.76%
3,451 $1.22 Million
Q1 2023

May 10, 2023
BUY
$283.23 - $323.1 $69,957 - $79,805
247 Added 11.56%
2,384 $750,000
Q4 2022

Feb 13, 2023
SELL
$285.76 - $321.48 $207,176 - $233,073
-725 Reduced 25.33%
2,137 $617,000
Q3 2022

Nov 09, 2022
BUY
$273.83 - $305.53 $222,897 - $248,701
814 Added 39.75%
2,862 $830,000
Q2 2022

Aug 10, 2022
BUY
$234.96 - $292.55 $27,960 - $34,813
119 Added 6.17%
2,048 $578,000
Q1 2022

May 12, 2022
BUY
$221.42 - $260.97 $45,169 - $53,237
204 Added 11.83%
1,929 $504,000
Q4 2021

Jan 27, 2022
BUY
$177.01 - $223.45 $232,591 - $293,613
1,314 Added 319.71%
1,725 $379,000
Q3 2021

Nov 12, 2021
SELL
$181.39 - $202.99 $67,114 - $75,106
-370 Reduced 47.38%
411 $74,000
Q2 2021

Aug 06, 2021
SELL
$187.49 - $221.1 $39,560 - $46,652
-211 Reduced 21.27%
781 $158,000
Q1 2021

May 13, 2021
BUY
$207.02 - $241.31 $2,691 - $3,137
13 Added 1.33%
992 $213,000
Q4 2020

Feb 09, 2021
BUY
$207.01 - $276.09 $19,044 - $25,400
92 Added 10.37%
979 $232,000
Q3 2020

Nov 12, 2020
SELL
$255.65 - $303.1 $76,439 - $90,626
-299 Reduced 25.21%
887 $241,000
Q2 2020

Aug 05, 2020
BUY
$225.48 - $295.8 $116,347 - $152,632
516 Added 77.01%
1,186 $344,000
Q1 2020

Apr 30, 2020
BUY
$199.77 - $247.81 $51,141 - $63,439
256 Added 61.84%
670 $159,000
Q4 2019

Feb 04, 2020
SELL
$166.71 - $223.91 $29,674 - $39,855
-178 Reduced 30.07%
414 $91,000
Q3 2019

Nov 07, 2019
SELL
$166.23 - $187.09 $250,508 - $281,944
-1,507 Reduced 71.8%
592 $100,000
Q2 2019

Jul 19, 2019
SELL
$164.61 - $190.37 $97,613 - $112,889
-593 Reduced 22.03%
2,099 $385,000
Q1 2019

May 13, 2019
BUY
$163.73 - $194.7 $82,356 - $97,934
503 Added 22.98%
2,692 $496,000
Q4 2018

Feb 12, 2019
BUY
$151.91 - $192.21 $30,078 - $38,057
198 Added 9.94%
2,189 $362,000
Q3 2018

Nov 06, 2018
BUY
$167.73 - $192.74 $22,475 - $25,827
134 Added 7.22%
1,991 $384,000
Q2 2018

Jul 25, 2018
SELL
$145.72 - $169.96 $291 - $339
-2 Reduced 0.11%
1,857 $315,000
Q1 2018

May 10, 2018
BUY
$151.6 - $177.13 $214,665 - $250,816
1,416 Added 319.64%
1,859 $303,000
Q4 2017

Jan 30, 2018
SELL
$137.28 - $155.55 $35,555 - $40,287
-259 Reduced 36.89%
443 $66,000
Q3 2017

Nov 03, 2017
BUY
$148.13 - $162.24 $103,987 - $113,892
702
702 $107,000

Others Institutions Holding VRTX

# of Institutions
1,760
Shares Held
228M
Call Options Held
1.63M
Put Options Held
1.47M
View Full List

About VERTEX PHARMACEUTICALS INC

VRTX Quotes by TradingView
  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $125B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Bessemer Group Inc Portfolio

Follow Bessemer Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bessemer Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bessemer Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email